Hong Kong stock abnormal movement | Kangfang Biosciences (09926.HK) rose more than 5% in early trading. The first patient was enrolled in the phase III clinical study of Yiwosi therapy for pancreatic cancer.
According to the Wisdom Financial APP, Kangfang Biology (09926.HK) soared more than 5% in the morning session. As of press time, it was up 3.84% at HK$148.9, with a turnover of HK$525 million.
Latest
